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Pertussis is still among the principal causes of death worldwide, and its incidence is increasing even in countries with
high vaccine coverage. Although all age groups are susceptible, it is most severe in infants too young to be protected
by currently available vaccines. To induce strong protective immunity in neonates, we have developed BPZE1, a live
attenuated Bordetella pertussis strain to be given as a single-dose nasal vaccine in early life. BPZE1 was developed by
the genetic inactivation or removal of three major toxins. In mice, BPZE1 was highly attenuated, yet able to colonize
the respiratory tract and to induce strong protective immunity after a single nasal administration. Protection against B.
pertussis was comparable to that induced by two injections of acellular vaccine (aPV) in adult mice, but was
significantly better than two administrations of aPV in infant mice. Moreover, BPZE1 protected against Bordetella
parapertussis infection, whereas aPV did not. BPZE1 is thus an attractive vaccine candidate to protect against
whooping cough by nasal, needle-free administration early in life, possibly at birth.
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Introduction
Whooping cough, or pertussis, is a severe childhood disease
responsible for high mortality rates before the introduction of
effective vaccines in the second half of the 20th century. The
success of these vaccines has led to the opinion that the disease
is essentially under control, although worldwide 200,000 to
400,000 pertussis-linked deaths are still recorded annually,
and the disease still ranks sixth among the causes of mortality
due to infectious agents [1]. Although mostly prevalent in
developing countries, the disease is also re-emerging in the
developed world [2,3], including the United States, where the
incidence has increased nearly 10-fold over the last 20 y [4].
Unexpectedly, the epidemiology of pertussis has changed in
countries with high vaccine coverage, where cases of adoles-
cent and adult pertussis are increasingly frequent [5]. This is
probably due to progressive waning of vaccine-mediated
immunity during adolescence. Often atypical and therefore
difﬁcult to diagnose, pertussis is generally not life-threatening
in adults and in many cases remains unnoticed. However,
infected adults constitute an important reservoir for trans-
mission of the disease to very young children, too young to be
fully vaccinated, and therefore at risk to develop severe
disease associated with high mortality rates.
Pertussis vaccination usually begins at 2 mo of age, and
optimal protection requires at least three immunizations.
Generally, the three doses are given at 1- to 2-mo intervals,
implying that optimal protection is only achieved at the age
of 6 mo. To reduce the incidence of pertussis in the very
young and most vulnerable age groups, early immunization,
possibly at birth, would thus be highly desirable. However,
numerous studies in humans and in animal models have
suggested that the neonatal immune system is too immature
to effectively induce vaccine-mediated protective immunity
[6,7]. The IFN-c production especially, which is indicative of a
Th1 response that is essential to the development of
protective immunity to pertussis [8], appears to be signiﬁ-
cantly reduced in human newborns, compared to older
children or adults [9]. This is also reﬂected by the fact that
signiﬁcant amounts of antigen-speciﬁc IFN-c are only
produced after several months ( 6 mo) in children vacci-
nated with pertussis vaccines, especially with acellular
vaccines (aPV) [10].
Natural infection with Bordetella pertussis has long been
considered to induce strong and long-lasting immunity that
wanes later than vaccine-induced immunity [5,11]. Further-
more, infection with B. pertussis induces measurable antigen-
speciﬁc Th1-type immune responses even in very young
children (as young as 1 mo of age) [12]. These observations
suggest that live vaccines applicable by the nasal route, in
order to mimic as closely as possible natural infection, may be
attractive alternatives over the currently available vaccines.
In this report, we describe the development of such a live
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to diminish pathogenicity while maintaining the ability to
colonize and induce protective immunity. This vaccine
candidate was found to induce protection in infant mice
after a single intranasal administration that is superior to the
protection provided by the current aPV. In addition, it
provided protection against infection with Bordetella para-
pertussis, which was not seen after vaccination with aPV.
Results
Construction of B. pertussis BPZE1
Recent advances in the understanding of B. pertussis
virulence at the molecular level [13] have allowed us to
rationally design a strategy for attenuation by removing or
altering genes that are involved in the pathogenesis of
whooping cough. Three virulence factors were genetically
targeted: tracheal cytotoxin (TCT), pertussis toxin (PTX), and
dermonecrotic toxin (DNT).
TCT is responsible for the destruction of ciliated cells in
the trachea of infected hosts [14,15] and may thus be involved
in the cough syndrome. TCT is a breakdown product of
peptidoglycan in the cell wall of Gram-negative bacteria,
which generally internalize it into the cytosol by the AmpG
transporter protein to be re-utilized during cell wall biosyn-
thesis. B. pertussis AmpG is inefﬁcient in the internalization of
peptidoglycan breakdown products. We therefore replaced
the B. pertussis ampG gene by E. coli ampG. The resulting strain
expressed less than 1% residual TCT activity (Figure 1A).
PTX is a major virulence factor responsible for the systemic
effects of B. pertussis infections and is composed of an
enzymatically active moiety, called S1, and a moiety respon-
sible for binding to target cell receptors (for review, see [16]).
However, it is also one of the major protective antigens,
which has prompted us to replace the natural ptx genes by a
mutated version coding for an enzymatically inactive toxin.
This was achieved by replacing Arg-9 by Lys, and Glu-129 by
Gly in S1, two key residues involved in substrate binding and
catalysis, respectively. Allelic exchange was used to ﬁrst delete
the ptx operon, and then to insert the mutated version. The
presence of the relevant toxin analogs in the B. pertussis
culture supernatants was detected by immunoblot analysis,
although the mutant strain consistently produced slightly
lower levels of anti-PTX antibody reactive material than the
parental strain (Figure 1B).
Finally, allelic exchange was used to remove the dnt gene
(Figure 1C). Although the role of DNT in the virulence of B.
pertussis is not certain, it has been identiﬁed as an important
toxin in the closely related species Bordetella bronchiseptica and
displays lethal activity upon injection of minute quantities
(for review, see [16]).
In Vitro Characterization of B. pertussis BPZE1
Since some of the genetic alterations in BPZE1 may
potentially affect the bacterial cell wall synthesis, we
compared the size and shape, as well as the in vitro growth
rate, of BPZE1 with those of the parental strain BPSM (see
Materials and Methods for reference). The growth rate of
BPZE1 did not differ from that of BPSM (Figure 2A), and no
difference in bacterial shape or size was detected between
BPZE1 and BPSM, as evidenced by electron microscopy
analysis (Figure 2B). However, the cell wall of BPZE1
appeared to be consistently somewhat thinner than that of
BPSM.
To determine whether the absence or alterations of any of
the targeted toxins in BPZE1 affect adherence properties of
B. pertussis, we compared the attachment rates of BPZE1 with
those of BPSM, using the human pulmonary epithelial cell
line A549 and the murine macrophage cell line J774, two
cellular models often used to study the adherence of B.
pertussis. No statistically signiﬁcant difference in the adher-
ence capacities to either cell line was observed between the
two strains (Figure 2C).
Attenuation of B. pertussis BPZE1
To determine whether the mutations introduced into B.
pertussis BPZE1 have resulted in attenuation, yet allow the
organism to colonize the respiratory tract, 8-wk-old Balb/C
mice were intranasally infected with BPZE1 or BPSM, and
colonization was followed over time. BPZE1 was able to
colonize and persist in the lungs of mice as long as BPSM
(Figure 3A). However, the peak of multiplication seen 7 d
after infection with BPSM was consistently lacking in mice
infected with BPZE1. Studies done with strains mutated in
individual toxin genes indicated that this is due to the
mutations in the ptx locus (unpublished data). When the lungs
were examined for histopathological changes and inﬂamma-
tory inﬁltration, infection with BPSM was found to induce
strong peri-bronchiovascular inﬁltrates and inﬂammatory
cell recruitment 7 d after infection, associated with a strong
hypertrophy of the bronchiolar epithelial cells (Figure 3B). In
contrast, no such changes were seen in BPZE1-infected
animals, and the histology of the BPZE1-infected mice was
similar to that of the control mice that had received sterile
phosphate-buffered saline (PBS) instead of the bacteria.
Similar results were obtained when infant mice (3 wk old)
were used instead of adult mice (see Figure S1) The BPSM
infection–induced inﬂammation lasted for at least 2 mo
(unpublished data). These results indicate that the mutations
introduced into BPZE1 have resulted in drastic attenuation,
but allow the bacteria to colonize and persist for up to 1 mo.
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Synopsis
Although vaccination has strongly reduced the incidence of
whooping cough in many countries, this disease still causes
approximately 300,000 deaths per year, mainly in young children
that are not fully vaccinated. Efficient protection against pertussis
requires at least three vaccine doses and is not achieved before the
age of 6 mo. A new strategy to induce strong protective immunity in
neonates is to mimic as closely as possible natural infection without
inducing the disease, by the use of a live attenuated B. pertussis
strain to be given as a single-dose nasal vaccine. The authors
examined in the mouse model the efficacy of a genetically
attenuated strain, BPZE1. This strain colonizes the mouse respiratory
tract, but appears to be highly attenuated as evidenced by
histopathological studies. In addition, a single nasal administration
of this strain protects against challenge with virulent B. pertussis
better than two administrations of acellular vaccine in infant mice.
Moreover, BPZE1 provides protection against infection with
Bordetella parapertussis responsible for a milder pertussis-like
syndrome, which was not seen after vaccination with acellular
vaccine. These results show that BPZE1 could be an efficient, single-
dose nasal vaccine to protect early in life against whooping cough.To test whether intranasal vaccination with BPZE1 may
predispose mice to other respiratory infections, BPZE1-
vaccinated mice were infected with Mycobacterium tuberculosis,
the most prevalent bacterial pathogen of the respiratory
tract, and the mycobacterial colony counts were determined 1
and 5 wk after infection. No signiﬁcant difference was
observed between mice immunized with BPZE1 prior to M.
tuberculosis infection and those that had received PBS instead
of BPZE1 (Figure 3C).
Protection against B. pertussis Challenge after Intranasal
Vaccination of Adult Mice with BPZE1
To evaluate the protection offered by BPZE1, we compared
the effect of a single intranasal administration of this strain
to 8-wk-old Balb/C mice on the subsequent colonization by
the wild-type challenge strain BPSM with that of two
intraperitoneal (ip) immunizations with 1/5 of a human dose
of aPV. This aPV immunization protocol has been described
as the best to correlate with pertussis vaccine efﬁcacy in
human clinical trials [17,18]. As shown by the total clearance
of bacterial colony counts in the lungs 7 d after challenge
infection, a single intranasal administration of BPZE1 and
two ip immunizations with aPV provided similar levels of
protection (Figure 4A). High bacterial loads were found in
the control mice that had received two injections of PBS
instead of the vaccine.
Protection against B. pertussis Challenge after Intranasal
Vaccination of Infant Mice with BPZE1
Since the principal targets of novel pertussis vaccines are
young infants, which are not protected with the currently
available vaccines, we have developed an infant (3-wk-old)
mouse model [19] and used it here to compare the efﬁciency
of vaccination with BPZE1 with that of vaccination with aPV.
A single nasal administration of BPZE1 fully protected infant
mice against challenge infection (Figure 4B), as complete
bacterial clearance was observed in the lungs 1 wk after
challenge. In contrast, substantial numbers of bacteria
remained in the aPV-vaccinated animals 1 wk after challenge
infection. The difference in bacterial load between the
BPZE1-vaccinated and the aPV-vaccinated mice was statisti-
cally signiﬁcant, indicating that in the infant mouse model, a
single intranasal administration with BPZE1 provides better
protection than two systemic administrations of aPV.
In addition, we consistently observed a strong reduction in
the bacterial load of the challenge strain 3 h after admin-
istration when the mice had been immunized with BPZE1
compared to the aPV-immunized animals (Figure 4C),
indicating that vaccination with BPZE1 reduces the suscept-
ibility to infection by the challenge strain. This effect was
seen in both 8-wk-old and in infant mice. In contrast, aPV had
no effect on the bacterial counts 3 h after infection, when
compared to the control mice.
Protection against B. parapertussis Challenge after
Intranasal Vaccination with BPZE1
There is increasing concern about B. parapertussis infection
in children, especially in immunized populations [20,21]. B.
parapertussis causes a milder pertussis-like syndrome, the
frequency of which is probably largely underestimated.
Furthermore, the incidence of B. parapertussis infections has
been increasing over the last decades, possibly due to the fact
that pertussis vaccines are known to have low or no
protective efﬁcacy against B. parapertussis [22,23]. In contrast,
infection by B. pertussis has recently been reported to protect
against B. parapertussis infection in the mouse model [24]. We
therefore assessed BPZE1 for protection against B. para-
pertussis using the infant mouse model. Whereas two admin-
istrations of aPV did not provide any protection against B.
parapertussis, a single intranasal administration of BPZE1
Figure 1. Characterization of B. pertussis BPZE1
(A) TCT present in culture supernatants of BPSM and BPZE1 expressed as means of nM/OD540nm (6 standard error) of three separate cultures for each
strain.
(B) Immunoblot analysis of PTX production in the culture supernatants of BPSM (lane 1) and BPZE1 (lane 2). The sizes of the molecular weight (Mr)
markers are expressed in kDa and given in the left margin.
(C) Southern blot analysis of the dnt locus in BPSM (lane 1) and BPZE1 (lane 2). The lengths of the size markers are indicated in base pairs (bp) are shown
in the left margin.
DOI: 10.1371/journal.ppat.0020065.g001
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of B. parapertussis counts in the lungs of the vaccinated mice 1
wk after challenge (Figure 4D).
Immune Responses Induced by BPZE1 Vaccination
Although the mechanisms of protective immunity against
B. pertussis infection are not yet completely understood, clear
evidence of a role for both B cells and IFN-c has been
demonstrated in mice [18]. Vaccination of infant mice with
either one nasal dose of BPZE1 or two ip administrations of
aPV induced high titers of serum immunoglobulin G (IgG)
against ﬁlamentous hemagglutinin (FHA) (Figure 5A), a major
surface antigen of B. pertussis [25], and against PTX (Figure
5B), both present in aPV, as well as against a B. pertussis whole
cell lysate (Figure 5C). Following B. pertussis challenge, positive
anamnestic responses were measured in BPZE1- and in aPV-
vaccinated animals, as indicated by an increase in anti-FHA,
anti-PTX, and anti-B. pertussis whole cell lysate IgG titers,
compared to primary responses before B. pertussis infection.
Similar results were obtained in 8-wk-old mice, as shown for
the anti-FHA responses in Figure S2. Examination of the anti-
FHA IgG1/IgG2a ratios showed that these ratios were higher
after aPV administration, characteristic of a Th2-type
response, than after BPZE1 vaccination (Figure 5D). After
challenge, the anti-FHA-IgG1/IgG2a ratio remained substan-
tially higher in the aPV-vaccinated mice than in the BPZE1-
vaccinated animals.
Analysis of B. pertussis antigen-speciﬁc cytokine patterns
induced by BPZE1 or aPV vaccination of 8-wk-old mice
conﬁrmed that BPZE1 administration favors a stronger Th1-
type response than aPV vaccination. This was revealed by the
fact that the ratios of IFN-c over IL-5 produced by
splenocytes stimulated with FHA or PTX, or with the
polyclonal activator ConA were signiﬁcantly higher in BPZE1
vaccinated mice than in aPV vaccinated mice (Figure 5E). For
technical reasons, these experiments could only be per-
formed in adult mice.
Discussion
Pertussis is the ﬁrst infectious disease whose incidence is
increasing in countries with high vaccine coverage, high-
lighting the limits of current vaccine strategies. The fact that
natural B. pertussis infection, even very early in life, is able to
induce a strong and long-lasting Th1 response [12] prompted
us to develop a live attenuated B. pertussis vaccine strain to be
given by the nasal route as an alternative over the currently
available vaccines.
On the basis of experimental infections of primates, Huang
et al. [26] in 1962 had already come to the conclusion that
ultimate protection against whooping cough probably best
follows a live B. pertussis inoculation. In veterinary medicine,
attenuated Bordetella strains have been used to vaccinate
against bordetellosis in dogs and piglets. A live attenuated
Bordetella bronchiseptica strain has been shown to provide
strong protection against kennel cough in dogs [27] after
nasal administration. This protection was seen as early as 48 h
after vaccination. Intranasal vaccination with live attenuated
B. bronchiseptica has also been shown to protect against
atrophic rhinitis in 2-d-old piglets [28], indicating that in a
live attenuated form, Bordetella vaccines can be highly active
in newborn animals.
Previous attempts to genetically attenuate B. pertussis as a
live vaccine candidate have met with rather limited success.
Based on a strategy used for the successful attenuation of
Salmonella vaccine strains [29], Roberts et al. [30] have deleted
the aroA gene of B. pertussis. The aroA mutant was indeed
highly attenuated, but it had also lost its capacity to colonize
the respiratory tract of the intranasally vaccinated animals,
and induced protective immunity only after repeated
administrations of high doses. We took advantage of the
knowledge on the molecular mechanisms of B. pertussis
virulence and developed the highly attenuated strain BPZE1.
This strain contains genetic alterations leading to the absence
Figure 2. Phenotypic Characterization of B. pertussis BPZE1
(A) Growth rates of BPSM (solid line) and BPZE1 (dotted line) in liquid
culture.
(B) Electron micrographs representative of BPSM (left) and BPZE1 (right)
grown in liquid medium for 24 h.
(C) In vitro adherence of BPSM (filled columns) and BPZE1 (open
columns) to human pulmonary epithelial A549 cells (left) and murine
macrophage-like J774 cells (right). The results are expressed as means (6
standard error) of percentages of binding bacteria relative to the bacteria
present in the inoculum from three different experiments.
DOI: 10.1371/journal.ppat.0020065.g002
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contrast to the aroA mutant, this strain was able to colonize
the mouse respiratory tract and to provide full protection
after a single intranasal administration. The protection in
adult mice was indistinguishable from that induced by two
administrations of 1/5 of a human dose of aPV. An important
difference, however, was seen in infant mice, in which a single
administration of BPZE1 fully protected, whereas aPV only
offered partial protection. In the context of the difﬁculties to
induce protection in infants early in life with the currently
available vaccines, these results provide hope for the
development of novel vaccination strategies that may be
used in the very young children, possibly at birth. In addition,
BPZE1 protected against B. parapertussis, whereas aPV did not.
Therefore the use of BPZE1 should also have an impact on
the incidence of whooping cough caused by B. parapertussis in
infants, provided that potential programmatic obstacles to
replace the current vaccines with a live attenuated strain can
be overcome.
Although the recent replacement of ﬁrst generation,
whole-cell vaccines by new aPV in many countries has
signiﬁcantly reduced the systemic adverse reactions observed
with whole-cell vaccines, it has not abolished the need for
repeated vaccination to achieve protection. This makes it
unlikely to obtain protection in very young children (,6 mo)
that present the highest risk to develop severe disease. In
addition, the wide-spread use of aPV has revealed new,
unforeseen problems. Repeated administration of aPV may
cause extensive swelling at the site of injection [31]. In
approximately 5% of the cases, this swelling involves almost
the entire limb and lasts for more than a week. Although the
mechanism of this swelling has not been characterized yet, it
has been proposed to be due to an Arthus hypersensitivity
reaction caused by high antibody levels induced by the
primary immunization [32]. However, it could also be related
Figure 3. In Vivo Characterization of B. pertussis BPZE1
(A) Lung colonization by BPSM (solid lines) and BPZE1 (dotted lines) of adult mice infected intranasally with 10
6 CFU of BPZE1 or BPSM. The results are
expressed as mean (6 standard error) CFUs from three to four mice per group, and are representative of two separate experiments. The dashed line
represents the limit of bacterial counts.
(B) Histological analysis of lungs from BPZE1 (upper panel) or BPSM-infected (middle panel) adult mice compared to controls given PBS (lower panel).
One week after infection, the lungs were aseptically removed and fixed in formaldehyde. Sections were stained with hematoxylin and eosin, and
examined by light microscopy.
(C) Susceptibility of BPZE1-infected mice to infection by M. tuberculosis. Balb/C mice were infected intranasally with 10
6 CFU of BPZE1 (filled columns) or
received PBS (open columns) and were intranasally infected one week later with 5310
4 M. tuberculosis H37Rv. One week (left columns) and 5 wk (right
columns) after M. tuberculosis infection, the M. tuberculosis CFUs present in the lungs were counted. The results are expressed as mean (6 standard
error) CFUs from four mice per group.
DOI: 10.1371/journal.ppat.0020065.g003
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whole-cell vaccines, aPV administration induces more Th2-
type cytokines in vaccinated children [10] and causes a delay
in the Th1 development (F. Mascart, M. Hainaut, A. Peltier, V.
Verscheure, J. Levy, and C. Locht, unpublished data). Delayed
maturation of Th1 function has been associated with a risk
for atopy in genetically pre-disposed individuals [33]. The two
mechanisms are not mutually exclusive. Compared to aPV,
the immune response to BPZE1 administration is less biased
towards the Th2 arm, and since BPZE1 is administered
mucosally, no swelling reaction can occur.
The use of live attenuated bacteria as vaccines raises the
issue of their biosafety. As such, they fall under the directives
and guidelines for genetically modiﬁed organisms susceptible
to be released into the environment. These guidelines and
directives describe several objectives that have to be met,
including hazard identiﬁcation and environmental risk
assessment [34]. Potential pathogenicity needs to be carefully
considered, especially in immunocompromised individuals,
such as those infected with HIV. The natural biology of B.
pertussis is particularly interesting in that regard. Although
pertussis in HIV-infected subjects has been described occa-
sionally, it is rather rare in AIDS patients [35]. In its
genetically attenuated form, B. pertussis would therefore not
be expected to cause major problems in HIV-infected
children, especially if severe AIDS is an exclusion criterion,
as it is for many vaccines. B. pertussis colonization is strictly
limited to the respiratory epithelium, without extrapulmo-
nary dissemination of the bacteria, which naturally excludes
systemic bacteremia of the BPZE1 vaccine strain. If never-
theless unforeseeable safety problems occurred, the vaccine
strain can be eliminated early following vaccination by the
use of macrolide antibiotics, such as erythromycine, to which
essentially all B. pertussis isolates are sensitive.
A further concern, as for any live vaccine, is the potential
release of the vaccine strain into the environment, and the
consequences of such a release. B. pertussis is predominantly a
human pathogen, and there is no known animal vector or
reservoir. Moreover, unlike B. bronchiseptica, survival of wild-
type B. pertussis in the environment is extremely limited [36].
Pertussis is usually spread by coughing individuals, and there
appears to be limited asymptomatic carriage [37]. Coughing
cannot be assessed in the mouse models used in this study.
However, due to the nature of the genetic alterations in
BPZE1, in particular the strong reduction of TCT and the
genetic inactivation of PTX, this strain would not be expected
to induce coughing. Active PTX has been shown to be
required for cough induction in a coughing rat model,
although the mechanism is not known [38]. If the vaccine
strain were nevertheless to be transmitted to non-vaccinated
individuals, this would at worst result in increased vaccine
coverage. The consequences of each of these potential
Figure 4. Protection against Bordetella Infection
Protection against B. pertussis in adult (A) and infant mice (B) and (C), or against B. parapertussis in infant mice (D). Mice immunized with BPZE1, aPV, or
PBS (naive) were challenged with BPSM (A), (B), and (C), or B. parapertussis (D), and lung CFU counts were determined 3 h (open columns) or 7 d (filled
columns) later. Results are expressed as mean (6 standard error) CFUs from three to four mice per group and are representative of two separate
experiments. (C) CFU counts 3 h after BPSM challenge in adult mice vaccinated with BPZE1 or aPV, compared to controls. The dashed lines in panels (A),
(B), and (D) represent the limit of bacterial counts.
DOI: 10.1371/journal.ppat.0020065.g004
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rapidly be controlled by antibiotic treatment if necessary.
Advantages of the use of BPZE1 include the relatively low
production costs, making it especially attractive for develop-
ing countries, its needle-free, easy, and safe mode of
administration, and its potential to induce mucosal immunity
in addition to systemic immunity. Although, surprisingly, the
role of mucosal immunity against pertussis has not been much
addressed, the fact that B. pertussis is a strictly mucosal
pathogen, makes it likely that mucosal immune responses may
contribute signiﬁcantly to protection. None of the currently
available vaccines induces any signiﬁcant mucosal response.
The use of live attenuated B. pertussis for mucosal
vaccination offers yet another advantage. B. pertussis can be
used for the presentation of heterologous antigens to the
respiratory mucosa (for review, see [39]) The use of BPZE1 as
a heterologous expression platform may thus be helpful for
the generation of multivalent vaccines against a variety of
respiratory pathogens. However, since intranasal delivery of
BPZE1 also induces strong systemic immune responses, as
shown here by both the high levels of anti-FHA antibodies
and of antigen-speciﬁc IFN-c production, it may also be used
for the production of antigens to which systemic immune
responses are desired.
Materials and Methods
Bordetella strains and growth conditions. The B. pertussis strains
used in this study are all derived from B. pertussis BPSM [40], and B.
parapertussis is a streptomycin-resistant derivative of strain 12822
(kindly provided by Dr. N. Guiso, Institut Pasteur de Paris, France).
All Bordetella strains were grown on Bordet-Gengou (BG) agar (Difco
Laboratories, Detroit, Michigan, United States) supplemented with
1% glycerol, 20% deﬁbrinated sheep blood, and 100 lg/ml
streptomycin. For cell adherence assays, exponentially growing B.
pertussis was inoculated at an optical density of 0.15 at 600 nm in 2.5-
ml modiﬁed Stainer-Scholte medium [41] containing 1 g/l hepta-
kis(2,6-di-o-methyl) b-cyclodextrin (Sigma, St. Louis, Missouri, United
States) and supplemented with 65 lCi/ml L-[
35S]methionine plus L-
[
35S]cysteine (NEN, Boston, Massachusetts, United States) and grown
for 24 h at 37 8C.The bacteria were then harvested by centrifugation,
washed three times in phosphate-buffered saline (PBS), and resus-
pended in RPMI 1640 (Gibco, Grand Island, New York, United States)
at the desired density. M. tuberculosis H37Rv was grown in Sauton
medium or on Middlebrook 7H11 agar (Difco Laboratories) at 37 8C.
Construction of B. pertussis BPZE1. The different steps followed to
construct B. pertussis BPZE1 can be found in Protocol S1. Brieﬂy, we
Figure 5. Immune Responses Induced in Infant Mice by BPZE1 or aPV Immunization
(A) Anti-FHA, (B) anti-PTX, (C) anti-B. pertussis IgG heavy and light chain (HþL) titers, and (D) anti-FHA IgG1/IgG2a ratios before (open columns) or 1 wk
after BPSM challenge (filled columns) in BPZE1 or aPV immunized 3-wk-old mice, compared to controls. (E) IFN-c to IL-5 ratios produced by FHA-, PTX-
or ConA-stimulated splenocytes from 8-wk-old mice vaccinated 2 mo before with BPZE1 (filled columns) or aPV (open columns), compared to controls
(gray columns). Antibodies and cytokines were measured in individual mice, and the results are expressed as mean values (6 standard error) for four
mice per group tested in triplicate.
DOI: 10.1371/journal.ppat.0020065.g005
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BPSM genome by Escherichia coli ampG. Next, allelic exchange was used
to delete the ptx operon and to then insert a mutated version coding
for enzymatically inactive PTX. Finally, the dnt gene was deleted from
the resulting B. pertussis strain.
Analysis of TCT production. For sensitive quantitation of TCT
production, culture supernatants of B. pertussis grown to logarithmic
phase were collected, subjected to solid phase extraction [42], and
derivatized with phenylisothiocyanate (PITC; Pierce Biotechnology,
Rockford, Illinois, United States). The resulting phenylthiocarbamyl
(PTC) derivatives were separated by reversed-phase high-perform-
ance liquid chromatography using a C8 column (Perkin Elmer,
Wellesley, California, United States) and detected at 254 nm. The
amount of B. pertussis PTC-TCT in each sample was determined by
comparing the peak area and elution time with an identically
processed TCT standard.
Cell-adherence assay. To analyze adherence properties of the B.
pertussis strains, their attachment rates to the human pulmonary
epithelial cell line A549 (ATCC n CCL-185) and the murine
macrophage cell line J774 (ATCC n TIB-67) were measured as
previously described [43].
Transmission electron microscopy. The single-droplet negative
staining procedure was used as described previously [44] with the
following modiﬁcations: 20 ll of a suspension at approximately 10
9
bacteria/ml were absorbed for 2 min onto form Formvar carbon-
coated nickel grids (400 mesh; Electron Microscopy Sciences EMS,
Washington, Pennsylvania, United States). After 30 s air-drying, the
grids were stained for 2 min with 20 ll of 2% phosphotungstic acid
(pH7) (EMS) and examined after air-drying under a transmission
electron microscope (Hitachi 7500; Hitachi, Tokyo, Japan) at 60 kV
and high resolution.
Intranasal infection and vaccination. The 3-wk-old and 8-wk-old
female Balb/C mice were kept under speciﬁc pathogen-free
conditions, and all experiments were carried out under the
guidelines of the Institut Pasteur de Lille animal study board.
Mice were intranasally infected with approximately 4 3 10
6 bacteria
in 20-ll PBS, and kinetics of colony-forming units (CFU) in the
lungs were measured as previously described [45]. For vaccination
with aPV (Tetravac; Aventis-Pasteur, Lyon, France), mice were
immunized ip with 20% of the human dose and boosted 1 mo later
using the same dose. For challenge infections with Bordetella, mice
were intranasally infected 2 mo after vaccination with approx-
imately 4 3 10
6 BPSM or B. parapertussis in 20-ll PBS. For challenge
infection with M. tuberculosis, mice were intranasally infected with 5
3 10
4 M. tuberculosis H37Rv in 20-ll PBS 1 wk after vaccination with
BPZE1.
Antibody determination. Sera were collected, and antibody titers
were estimated by enzyme-linked immunosorbent assays (ELISA) as
previously described [45].
Cytokine assays. Spleen cells from individual mice were tested at
different time points after immunization for in vitro cytokine
production in response to heat-killed B. pertussis BPSM (10
6 cells/
ml), 5.0 lg/ml PTX (puriﬁed from B. pertussis BPGR4 [46] as previously
described [47], and heat-inactivated at 80 8C for 20 min), 5.0 lg/ml
FHA (puriﬁed from B. pertussis BPRA [48] as previously described
[49]), 5 lg/ml concanavalin A (Sigma) or medium alone as control.
Supernatants were removed from triplicate cultures after 72-h
incubation at 37 8C and 5% CO2, and IFN-c and IL-5 concentrations
were determined by immunoassays (BD OptEIA set; PharMingen, San
Diego, California, United States).
Statistical analysis. The results were analyzed using the unpaired
Student t test and the Kruskal-Wallis test followed by the Dunn post-
test (GraphPad Prism program) when appropriate. Differences were
considered signiﬁcant at p   0.05.
Supporting Information
Figure S1. Lung Colonization and Histological Analysis of Lungs from
BPSM- or BPZE1-Infected Infant Mice
(A) The 3-wk-old Balb/C mice were infected intranasally with 10
6 CFU
of BPSM (solid lines) or BPZE1 (dotted lines). The results are
expressed as mean (6 standard error) CFUs from three to four mice
per group and are representative of two separate experiments. The
dashed line represents the limit of bacterial counts.
(B) Histological analysis of lungs from BPZE1 (upper panel) or BPSM-
infected (middle panel) 3-wk-old mice compared to controls given
PBS (lower panel). One week after infection, the lungs were
aseptically removed and ﬁxed in formaldehyde. Sections were stained
with toluidine blue and examined by light microscopy.
Found at DOI: 10.1371/journal.ppat.0020065.sg001 (198 KB PPT).
Figure S2. Immune Responses Induced in Adult Mice by BPZE1 or
aPV Immunization
Anti-FHA (A), anti-PTX (B), anti-B. pertussis IgG heavy and light chain
(HþL) titers (C), and anti-FHA IgG1/IgG2a ratios (D) before (open
columns) or 1 wk after BPSM challenge (ﬁlled columns) in BPZE1 or
aPV immunized 8-wk-old mice, compared to controls. Antibodies
were measured in individual mice, and the results are expressed as
mean values (6 standard error) for four to ﬁve mice per group.
Found at DOI: 10.1371/journal.ppat.0020065.sg002 (46 KB PPT).
Protocol S1. Supplementary Materials and Methods
Found at DOI: 10.1371/journal.ppat.0020065.sd001 (30 KB DOC).
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